Skip to main content

Table 3 Base case clinical results: incremental life years per 1,000 patients

From: The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

Cohort Evaluated

Incremental Life Years

PMO Patients (100% Female), age 69 years, T-Score = −3.0

 

historical vertebral + incident vertebral fracture

 

 Teriparatide vs. No Treatment

132

 Teriparatide vs. bisphosphonate

102

incident vertebral fracture

 

 Teriparatide vs. No Treatment

102

 Teriparatide vs. bisphosphonate

77

GIOP Patients (80% Female), age 69 years, T-Score = −2.5

 

historical vertebral + incident vertebral fracture

 

 Teriparatide vs. No Treatment

153

 Teriparatide vs. bisphosphonate

117

incident vertebral fracture

 

 Teriparatide vs. No Treatment

140

 Teriparatide vs. bisphosphonate

106